Original Paper
Association between Deposition of Beta-Amyloid and Pathological Prion
Protein in Sporadic Creutzfeldt-Jakob Disease
Laura Debatina, Johannes Strefferb, Markus Geissenc, Jakob Matschkec,
Adriano Aguzzia, Markus Glatzela, c
aInstitute of Neuropathology, and
bDivision of Psychiatry Research, University Hospital Zurich, Zurich,
Switzerland;
cInstitute of Neuropathology, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
Address of Corresponding Author
Neurodegenerative Dis (DOI: 10.1159/000121389)
----------------------------------------------------------------------------
----
Key Words
Sporadic Creutzfeldt-Jakob disease
Alzheimer's disease
Deposition of -amyloid
Prion protein
----------------------------------------------------------------------------
----
Abstract
Background: Alzheimer's disease (AD) and prion diseases such as sporadic
Creutzfeldt-Jakob disease (sCJD) share common features concerning their
molecular pathogenesis and neuropathological presentation and the
coexistence of AD and CJD in patients suggest an association between the
deposition of the proteolytically processed form of the amyloid precursor
protein, -amyloid (A), which deposits in AD, and the abnormal form of the
prion protein, PrPSc, which deposits in sCJD. Methods: We have characterized
sCJD patients (n = 14), AD patients (n = 5) and nondemented controls (n = 5)
with respect to the deposition of PrPSc and A morphologically, biochemically
and genetically and correlated these findings to clinical data. Results:
sCJD-diseased individuals with abundant deposits of A present with a
specific clinicopathological profile, defined by higher age at disease
onset, long disease duration, a genetic profile and only minimal amounts of
PrPSc in the cerebellum. Conclusion: The co-occurrence of pathological
changes typical for sCJD and AD in combination with the inverse association
between accumulation of A and PrPSc in a subgroup of sCJD patients is
indicative of common pathways involved in the generation or clearance of A
and PrPSc in a subgroup of sCJD patients.
Copyright © 2008 S. Karger AG, Basel
----------------------------------------------------------------------------
----
Author Contacts
Markus Glatzel
Institute of Neuropathology, University Medical Center Hamburg-Eppendorf
Martinistrasse 52, DE-20246 Hamburg (Germany)
Tel. +49 40 42 803 2218, Fax +49 40 42 803 4929
E-Mail
m.glatzel@uke.uni-hamburg.de
http://content.karger.com/produktedb...file=000121389
Singeltary, Sr et al. JAMA.2001; 285: 733-734.
Diagnosis and Reporting of Creutzfeldt-Jakob Disease
Since this article does not have an abstract, we have provided the first 150
words of the full text and any section headings.
To the Editor:
In their Research Letter, Dr Gibbons and colleagues1 reported that the
annual US death rate due to Creutzfeldt-Jakob disease (CJD) has been stable
since 1985. These estimates, however, are based only on reported cases, and
do not include misdiagnosed or preclinical cases. It seems to me that
misdiagnosis alone would drastically change these figures. An unknown number
of persons with a diagnosis of Alzheimer disease in fact may have CJD,
although only a small number of these patients receive the postmortem
examination necessary to make this diagnosis. Furthermore, only a few states
have made CJD reportable. Human and animal transmissible spongiform
encephalopathies should be reportable nationwide and internationally.
Terry S. Singeltary, Sr
Bacliff, Tex
1. Gibbons RV, Holman RC, Belay ED, Schonberger LB. Creutzfeldt-Jakob
disease in the United States: 1979-1998. JAMA. 2000;284:2322-2323. FREE FULL
TEXT
http://jama.ama-assn.org/cgi/content...urcetype=HWCIT
see my full text on Alzheimers and CJD blog here ;
http://betaamyloidcjd.blogspot.com/2...n-of-beta.html
TSS